News | September 02, 2021
Granules India receive DRDO licence to manufacture and market 2-DG
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Subscribe To Our Newsletter & Stay Updated
